BioMed Central

AION Labs, In Continued Partnership with BioMed X, Launches First 2024 Global Call for Applications: AI/ML Platform for Targeting RNA with Small Molecules

Retrieved on: 
Tuesday, February 20, 2024
Merck, Amazon Web Services, Chemistry, AI, RNA, Invention, AION, BioMed Central, Research, AWS, Vaccine

REHOVOT, Israel and HEIDELBERG, Germany, Feb. 20, 2024 /PRNewswire/ -- AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, and German independent research institute BioMed X, announced today the launch of its latest global call for applications to identify computational biologists, biomedical scientists and inventors to form a new startup at AION Labs' headquarters in Rehovot, Israel.

Key Points: 
  • AION Labs' next startup will focus on the development of an AI/ML computational platform to identify functional regions in RNA that can be targeted with small molecules.
  • However, recent developments have shown that RNA levels can be modulated using small molecules, which has resulted in several candidate drugs currently in clinical trials.
  • RNA targeting is an emerging field and small molecule discovery of RNA modulators remains a significant challenge.
  • Further details about this call for applications can be found on the AION Labs website: www.aionlabs.com .

Sahmyook University Researchers Developed Hip-Assist Robot to Advance Fitness in the Elderly

Retrieved on: 
Thursday, February 15, 2024
Robotics, BioMed Central, Ratio, Research, Geriatrics, Samsung Electronics, Walking, Exercise, Risk, Facial muscles, Sahmyook University, TUG, Science, Movement, Comparison, RUSI, Gangsta Walking

Recently, researchers from Sahmyook University in Korea have developed EX1, an exercise assistance robot, with the goal to amplify physical function and strength in senior individuals.

Key Points: 
  • Recently, researchers from Sahmyook University in Korea have developed EX1, an exercise assistance robot, with the goal to amplify physical function and strength in senior individuals.
  • Led by Professor Wan-hee Lee from Sahmyook University College of Health Science, Korea, a collaborative team of researchers, Noble County, and Samsung Electronics, assessed the effectiveness of EX1 in executing a four-week combined exercise program for older adults.
  • This will further expand the global wearable robot market, promoting further research and commercialization," concludes an optimistic Prof. Lee.
  • Title of original paper:    Effect of 4–weeks exercise program using wearable hip–assist robot (EX1) in older adults: one group pre– and post– test

AION Labs Launches New Startup Leveraging Machine Learning for Molecular Glue Discovery

Retrieved on: 
Tuesday, January 30, 2024
Disease, AION, Patient, Biology, Research, Deep learning, Amazon Web Services, Computational biology, BioMed Central, University, AI, Algorithm, AWS, Protein, Doctor of Philosophy, Machine learning, Merck, Treatment, Data science, Weizmann Institute of Science, Medical device

REHOVOT, Israel , Jan. 30, 2024 /PRNewswire/ -- AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, announced today the formation of TenAces Biosciences. TenAces is a startup developing a novel approach to discover new molecular glue therapies, leveraging machine learning  to enhance development of treatments for a range of conditions.

Key Points: 
  • TenAces is a startup developing a novel approach to discover new molecular glue therapies, leveraging machine learning  to enhance development of treatments for a range of conditions.
  • TenAces emerged from AION Labs' fifth startup challenge to develop an AI platform to identify naturally occurring protein interactions leading to targeted protein degradation.
  • The platform solution is expected to facilitate the discovery and development of molecular glue therapies for enhanced targeted protein degradation.
  • TenAces is taking a different approach, by applying machine learning to study the various interactions, protein pairs, and multi-dimensional features to predict new molecular glues.

BioMed Diagnostics to Attend VMX 2024

Retrieved on: 
Tuesday, January 9, 2024
Yeast, Learning, Food, Animal, VMX, Culture, BioMed Central, Orange County Convention Center, Dermatophyte, Environment, Tritrichomonas foetus, Bacteria, Human, Veterinarian, Growth

ORLANDO, Fla., Jan. 9, 2024 /PRNewswire/ -- BioMed Diagnostics, a leader in microbiological testing and a DCN Dx brand, is pleased to announce their attendance at VMX 2024, the world's leading veterinary expo and conference. While not exhibiting, BioMed representatives have set aside availability for meeting with veterinary professionals and attendees throughout the event.

Key Points: 
  • ORLANDO, Fla., Jan. 9, 2024 /PRNewswire/ -- BioMed Diagnostics, a leader in microbiological testing and a DCN Dx brand, is pleased to announce their attendance at VMX 2024 , the world's leading veterinary expo and conference.
  • Highlighting their commitment to veterinary health, BioMed representatives will discuss several key products at VMX 2024, including:
    InTray® DM: An enriched dermatophyte medium for detecting dermatophytes from clinical specimens.
  • Veterinary professionals interested in learning more about how BioMed's products can benefit their practices are encouraged to schedule a meeting during VMX 2024.
  • "We're excited to join VMX 2024 and connect with veterinary professionals," said Mitzi Rettinger, Chief Revenue Officer at DCN Dx.

Call for Application to Researchers for Joint Research Project between Ono Pharmaceutical and BioMed X

Retrieved on: 
Tuesday, January 9, 2024
BioMed Central, Research

OSAKA, Japan, Jan. 9, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Osaka, Japan) informed that it has started a new collaboration with BioMed X (Heidelberg, Germany) on cancer immunotherapies and has been inviting researchers who are interested in this research project via BioMed X.

Key Points: 
  • OSAKA, Japan, Jan. 9, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Osaka, Japan) informed that it has started a new collaboration with BioMed X (Heidelberg, Germany) on cancer immunotherapies and has been inviting researchers who are interested in this research project via BioMed X.
  • For details, please refer to the following BioMed X press release and application guidelines for the research project:
    BioMed X's press release dated December 19, 2023:

Call for Application to Researchers for Joint Research Project between Ono Pharmaceutical and BioMed X

Retrieved on: 
Tuesday, January 9, 2024
BioMed Central, Research

OSAKA, Japan, Jan. 9, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Osaka, Japan) informed that it has started a new collaboration with BioMed X (Heidelberg, Germany) on cancer immunotherapies and has been inviting researchers who are interested in this research project via BioMed X.

Key Points: 
  • OSAKA, Japan, Jan. 9, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Osaka, Japan) informed that it has started a new collaboration with BioMed X (Heidelberg, Germany) on cancer immunotherapies and has been inviting researchers who are interested in this research project via BioMed X.
  • For details, please refer to the following BioMed X press release and application guidelines for the research project:
    BioMed X's press release dated December 19, 2023:

Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients

Retrieved on: 
Monday, January 8, 2024
Blood pressure, Bradycardia, Risk, Orchestra, Collection, Consultant, Hypertension, Mortality, Disease, HOPE, Stroke, Comorbidity, Patient, Safety, Heart failure, Beat (music), BioMed Central, OSBP, Pharmaceutical industry

AVIM therapy is an investigational patented bioelectronic therapy, administered using a standard dual-chamber pacemaker, designed to immediately, substantially and persistently reduce blood pressure.

Key Points: 
  • AVIM therapy is an investigational patented bioelectronic therapy, administered using a standard dual-chamber pacemaker, designed to immediately, substantially and persistently reduce blood pressure.
  • Orchestra BioMed and Medtronic, Inc. (NYSE: MDT) (“Medtronic”) formed a strategic collaboration for the development and commercialization of AVIM therapy for hypertensive pacemaker patients in July 2022.
  • Orchestra BioMed is actively screening patients for enrollment in the BACKBEAT pivotal study.
  • The study will randomize approximately 500 patients 1:1 to AVIM therapy combined with continued medical therapy (treatment) or continued medical therapy and standard pacing alone (control).

BioMed Realty Strengthens Leadership Team with Key Officer Promotions

Retrieved on: 
Friday, January 5, 2024
Science, Commercial Building & Real Estate, Other Science, Construction & Property, Health, Technology, Other Technology, Other Health, IREM, Real estate, Multimedia, Business, Kellogg School, Virginia Commonwealth University, Cornell University, MBA, Melvin Swig, Certified Property Manager, Property management, Northwestern University, University, San Francisco Bay Area, BioMed Central, Management

These promotions are a testament to the Company’s commitment to fostering a team of exceptional leaders and recognizing outstanding talent within the Company.

Key Points: 
  • These promotions are a testament to the Company’s commitment to fostering a team of exceptional leaders and recognizing outstanding talent within the Company.
  • View the full release here: https://www.businesswire.com/news/home/20240105183449/en/
    “Since joining BioMed Realty, Tracy, Ed and Kevin have provided valuable and expert leadership across the Company's property management, development and investment disciplines,” said Tim Schoen, CEO of BioMed Realty.
  • Vu has played key roles on the Investments team since joining BioMed Realty in 2021, helping to expand the Company’s footprint in its core innovation markets.
  • BioMed Realty continues to demonstrate its commitment to fostering leadership excellence as the Company helps contribute to the expansion of the life science and technology sectors.

BioMed X Institute and Ono Pharmaceutical Launch New Collaboration in Cancer Research

Retrieved on: 
Friday, December 22, 2023
Biomedical Research, Immunotherapy, Partnership, Tumor microenvironment, Research, Cancer, Ono Pharmaceutical, Patient, Discovery, BioMed Central, Senior, Pharmaceutical industry

German research institute BioMed X and Ono Pharmaceutical, a Japanese pharmaceutical company, started a new joint research project on cancer immunotherapies.

Key Points: 
  • German research institute BioMed X and Ono Pharmaceutical, a Japanese pharmaceutical company, started a new joint research project on cancer immunotherapies.
  • Heidelberg, Germany, Dec 22, 2023 - (ACN Newswire) - BioMed X announced today a new joint research project with Ono Pharmaceutical Co., Ltd, marking the start of the collaboration between the German biomedical research institute and one of the largest pharmaceutical companies in Japan.
  • The new research team will join nine other research groups at the BioMed X Institute in Heidelberg, Germany.
  • Christian Tidona, Founder and Managing Director of the BioMed X Institute: "Oncology and immunology, including tumor immunology, are key areas of expertise at BioMed X.

USDA APHIS Announces Major Award to PlantPharm BioMed to Develop Edible COVID Vaccine for Animals

Retrieved on: 
Wednesday, December 13, 2023
Biotechnology, Infectious Diseases, Health, Veterinary, Pharmaceutical, Pet, Cat, Research, Plant, USDA, Edible, BioMed Central, Clinical trial, One Health, Vaccine, Animal, APHIS, Solid, COVID-19, Human, Dog, Environment, Livestock

PlantPharm BioMed, Ltd. has been awarded more than $900,000 by the U.S. Department of Agriculture Animal and Plant Health Inspection Service (USDA APHIS) to develop a stable, feed delivered SARS-CoV-2 (COVID-19) animal vaccine.

Key Points: 
  • PlantPharm BioMed, Ltd. has been awarded more than $900,000 by the U.S. Department of Agriculture Animal and Plant Health Inspection Service (USDA APHIS) to develop a stable, feed delivered SARS-CoV-2 (COVID-19) animal vaccine.
  • The edible vaccine will allow animals of multiple species whether wild or domestic to be easily vaccinated, thus breaking the animal-related path of the pandemic chain of COVID-19.
  • PlantPharm will produce an ‘Oral Solid Dose’ vaccine using the company’s proprietary production platform for plant-based vaccines using plants as surrogates thus becoming vaccine factories.
  • For more information about PlantPharm BioMed’s edible animal vaccine visit: https://plantpharm-biomed-40498911.hubspotpagebuilder.com/plant-based-ed...